Oncology Institute (TOIIW) Cost of Revenue (2021 - 2026)

Oncology Institute (TOIIW) has reported Cost of Revenue for 6 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $8.3 million, down 73.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $74.9 million (up 881.52% YoY), and the FY2025 annual result was $220.6 million, up 16813.96% from the prior year.
• Cost of Revenue was $8.3 million for Q1 2026 at Oncology Institute, down from $66.5 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $66.5 million in Q4 2025 and troughed at -$110.4 million in Q4 2024.
• Average Cost of Revenue over 5 years is $22.5 million, with a median of $34.5 million recorded in 2022.
• Year-over-year, Cost of Revenue surged 40886.44% in 2023 and sank 328.26% in 2024.
• Over 5 years, Cost of Revenue stood at $118000.0 in 2022, then soared by 40886.44% to $48.4 million in 2023, then sank by 328.26% to -$110.4 million in 2024, then soared by 160.27% to $66.5 million in 2025, then plunged by 87.56% to $8.3 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $8.3 million in Q1 2026, $66.5 million in Q4 2025, and $65000.0 in Q2 2025.